Table 1:
Patient Characteristics
| Variable Name | n = 75 |
|---|---|
| Age (Mean ± SD) | 58.1 ± 15.5 |
|
| |
| Female N,% | 52 (69.3%) |
|
| |
| Race N,% | |
| Black | 11 (14.7%) |
| White | 56 (74.7%) |
|
| |
| BMI (Mean ± SD) | 28.5 ± 6.5 |
|
| |
| Received Antibiotics prior to Diagnosis N,% | 56 (74.7%) |
|
| |
| Prior PPI use N,% | 41 (54.7%) |
|
| |
| History of Cirrhosis N,% | 5 (6.7%) |
|
| |
| Dietary restrictionsN,% | |
| No | 68 (90.7%) |
| Vegan | 1 (1.3%) |
| Vegetarian | 3 (4.0%) |
| Gluten Free | 1 (1.3%) |
| Lactose Free | 2 (2.7%) |
|
| |
| Smoking status | |
| Never | 39 (52.7%) |
| Former | 31 (41.9%) |
| Current | 4 (5.4%) |
|
| |
| Diagnosis of Irritable Bowel Syndrome N,% | 8 (11.3%) |
|
| |
| Baseline diarrhea or constipation N,% | |
| No | 54 (74.0%) |
| Diarrhea | 8 (11.0%) |
| Constipation | 9 (12.3%) |
| Both | 2 (2.7%) |
|
| |
| Baseline Bristol Score (Mean ± SD) | 3.1 ± 1.2 |
|
| |
| Ursodiol Use N,% | 0 (0.0%) |
|
| |
| Cholestyramine Use N,% | 2 (2.7%) |
|
| |
| Cholestid Use N,% | 1 (1.4%) |
|
| |
| CDI Treatment Regimen | |
| Metronidazole | 17 (22.7%) |
| Vancomycin | 58 (77.3%) |
|
| |
| Other current antibiotics (not for C diff) | 8 (10.7%) |
|
| |
| Test Used for Diagnosis N,% | |
| PCR | 35 (46.7%) |
| EIA Toxin | 40 (53.3%) |
|
| |
| Baseline Lab Values (Mean ± SD) | |
|
| |
| WBC | 12.9 ± 16.4 |
|
| |
| Hct | 40.6 ± 4.5 |
|
| |
| Plts | 252.7 ± 108.0 |
|
| |
| ALT | 42.3 ± 80.0 |
|
| |
| AST | 38.3 ± 75.9 |
|
| |
| Alkaline Phosphatase | 85.5 ± 46.5 |
|
| |
| T. Bilirubin | 0.6 ± 0.5 |
|
| |
| BUN | 20.9 ± 22.6 |
|
| |
| Cr | 1.7 ± 4.3 |
|
| |
| PT | 20.5 ± 23.9 |
|
| |
| INR | 1.3 ± 0.4 |